Zacks Investment Management Halozyme Therapeutics, Inc. Transaction History

Zacks Investment Management

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $1.18 Million - $1.52 Million	-37,027 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$31.82 - $40.75 $70,704 - $90,546	2,222 Added 6.38%	37,027 $1.49 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $127,027 - $153,278	3,302 Added 10.48%	34,805 $1.42 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $5,981 - $7,901	154 Added 0.49%	31,503 $1.43 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $20,861 - $27,165	528 Added 1.71%	31,349 $1.31 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $106,182 - $179,452	4,114 Added 15.4%	30,821 $1.32 Million
Q3 2020 Nov 16, 2020	SELL	$25.74 - $29.63 $6,872 - $7,911	-267 Reduced 0.99%	26,707 $702,000
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $438,327 - $723,172	26,974 New	26,974 $723,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

Stay updated on Zacks Investment Management with notifications on news.